Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways

Cell Death and Disease

Volumn 5, Issue 3, 2014, Pages

  Gunda, V ^a   Bucur, O ^b,c   Varnau, J ^d   Vanden Borre, P ^a   Bernasconi, M J ^a   Khosravi Far, R ^b   Parangi, S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c INSTITUTE OF BIOCHEMISTRY OF THE ROMANIAN ACADEMY   (Romania)

^d INDIANA UNIVERSITY   (United States)

Author keywords

Apoptosis; Orthotropic; Thyroid cancer; TRAIL

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BIM PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; DEATH RECEPTOR 5; EFFECTOR CASPASE; FLICE INHIBITORY PROTEIN; LEXATUMUMAB; MITOGEN ACTIVATED PROTEIN KINASE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THYROID CANCER; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CHROMONES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INDOLES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, SCID; MOLECULAR TARGETED THERAPY; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SULFONAMIDES; THYROID NEOPLASMS; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897463587     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.78     Document Type: Article

References (50)

1. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012; 62: 118-128.
2. Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 2007; 8: 148-156.
3. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009; 16: 17-44.
4. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007; 28: 742-762.
5. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008; 93: 3943-3949.
6. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 2008; 15: 191-205.
7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
8. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-867.
9. Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G et al. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. Mol Cancer Ther 2007; 6: 1070-1078.
10. Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH et al. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist 2011; 16: 296-309.
11. Nehs MA, Nagarkatti S, Nucera C, Hodin RA, Parangi S. Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer. Surgery 2010; 148: 1154-1162.
12. Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE et al. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab 2010; 95: 450-455.
13. Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 2010; 14: 1091-1108.
14. Malin D, Chen F, Schiller C, Koblinski J, Cryns VL. Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer. Clin Cancer Res 2011; 17: 5005-5015.
15. Merchant MS, Geller JI, Baird K, Chou AJ, Galli S, Charles A et al. Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors. J Clin Oncol 2012; 30: 4141-4147.
16. Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R et al. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol 2010; 21: 376-381.
17. Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007; 13: 6187-6194.
18. Ren B, Song K, Parangi S, Jin T, Ye M, Humphreys R et al. A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. Cancer Res 2009; 69: 3856-3865.
19. Zhang L, Zhang X, Barrisford GW, Olumi AF. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett 2007; 251: 146-157.
20. Bangert A, Cristofanon S, Eckhardt I, Abhari BA, Kolodziej S, Hacker S et al. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene 2012; 31: 4677-4688.
21. Morissette MC, Vachon-Beaudoin G, Parent J, Chakir J, Milot J. Increased p53 level, Bax/ Bcl-x(L) ratio, and TRAIL receptor expression in human emphysema. Am J Respir Crit Care Med 2008; 178: 240-247.
22. Bansal H, Seifert T, Bachier C, Rao M, Tomlinson G, Iyer SP et al. The transcription factor Wilms tumor 1 confers resistance in myeloid leukemia cells against the proapoptotic therapeutic agent TRAIL (tumor necrosis factor alpha-related apoptosis-inducing ligand) by regulating the antiapoptotic protein Bcl-xL. J Biol Chem 2012; 287: 32875-32880.
23. Fulda S. Tumor resistance to apoptosis. Int J Cancer 2009; 124: 511-515.
24. Dolloff NG, Mayes PA, Hart LS, Dicker DT, Humphreys R, El-Deiry WS. Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Sci Transl Med 2011; 3: 86ra50.
25. Zhao X, Cao M, Liu JJ, Zhu H, Nelson DR, Liu C. Reactive oxygen species is essential for cycloheximide to sensitize lexatumumab-induced apoptosis in hepatocellular carcinoma cells. PLoS One 2011; 6: e16966.
26. Wu XX, Kakehi Y. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner. Clin Cancer Res 2009; 15: 2039-2047.
27. Engesaeter B, Engebraaten O, Florenes VA, Maelandsmo GM. Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma. PLoS One 2012; 7: e45492.
28. Dieterle A, Orth R, Daubrawa M, Grotemeier A, Alers S, Ullrich S et al. The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Int J Cancer 2009; 125: 932-941.
29. Opel D, Naumann I, Schneider M, Bertele D, Debatin KM, Fulda S. Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma. Clin Cancer Res 2011; 17: 3233-3247.
30. Shao Y, Aplin AE. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res 2010; 70: 6670-6681.
31. Oikonomou E, Koc M, Sourkova V, Andera L, Pintzas A. Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance. PLoS One 2011; 6: e21632.
32. Nucera C, Nehs MA, Mekel M, Zhang X, Hodin R, Lawler J et al. A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid 2009; 19: 1077-1084.
33. Chan CM, Jing X, Pike LA, Zhou Q, Lim DJ, Sams SB et al. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res 2012; 18: 3580-3591.
34. Aplin AE, Kaplan FM, Shao Y. Mechanisms of resistance to RAF inhibitors in melanoma. J Invest Dermatol 2011; 131: 1817-1820.
35. Nucera C, Lawler J, Hodin R, Parangi S. The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? Oncotarget 2010; 1: 751-756.
36. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 2009; 94: 4107-4112.
37. Martelli AM, Tazzari PL, Tabellini G, Bortul R, Billi AM, Manzoli L et al. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-transretinoic acid, and ionizing radiation of human leukemia cells. Leukemia 2003; 1: 1794-1805.
38. Martinez-Paniagua MA, Baritaki S, Huerta-Yepez S, Ortiz-Navarrete VF, Gonzalez-Bonilla C, Bonavida B et al. Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis. Cell Cycle 2011; 10: 2792-2805.
39. Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, Bayer E et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 2000; 19: 5477-5486.
40. Zhu H, Guo W, Zhang L, Davis JJ, Wu S, Teraishi F et al. Enhancing TRAIL-induced apoptosis by Bcl-X(L) siRNA. Cancer Biol Ther 2005; 4: 393-397.
41. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2004; 11: 915-923.
42. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutationspecific gene expression profiles discovered by DNA microarray analysis. Oncogene 2005; 24: 6646-6656.
43. Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D et al. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One 2010; 5: e14124.
44. Ivanov VN, Bhoumik A, Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene 2003; 22: 3152-3161.
45. Berger A, Quast SA, Plotz M, Kuhn NF, Trefzer U, Eberle J. RAF inhibition overcomes resistance to TRAIL-induced apoptosis in melanoma cells. J Invest Dermatol 2013; 134: 430-440.
46. Leahomschi S, Molinsky J, Klanova M, Andera L, Peterka M, Gasova Z et al. Multi-level disruption of the extrinsic apoptotic pathway mediates resistance of leukemia cells to TNF-related apoptosis-inducing ligand (TRAIL). Neoplasma 2013; 60: 223-231.
47. Romano G, Acunzo M, Garofalo M, Di Leva G, Cascione L, Zanca C et al. MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. Proc Natl Acad Sci USA 2012; 109: 16570-16575.
48. Badmann A, Langsch S, Keogh A, Brunner T, Kaufmann T, Corazza N. TRAIL enhances paracetamol-induced liver sinusoidal endothelial cell death in a Bim- and Bid-dependent manner. Cell Death Dis 2012; 3: e447.
49. Antico Arciuch VG, Russo MA, Dima M, Kang KS, Dasrath F, Liao XH et al. Thyrocytespecific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. Oncotarget 2011; 2: 1109-1126.
50. Charles RP, Iezza G, Amendola E, Dankort D, McMahon M. Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse. Cancer Res 2011; 71: 3863-3871.